Tidal Vision, a Bellingham, WA-based biotechnology company improving critical industries with chitosan-based chemistries, raised $140M in Series B Funding.
Backers included Cambridge Companies SPG, Eni Next, Milliken & Company, KIRKBI Climate, Convent Capital, SWEN Capital Partners’ Blue Ocean Fund, MBX Capital, Oman Investment Authority’s IDO Investments, and more.
The company intends to use the funds to expand new infrastructure in Europe, Texas, and Ohio, and its R&D efforts.
Led by CEO Craig Kasberg, Tidal Vision specializes in scalable biomolecular solutions for critical industries, such as water treatment, agriculture, and material science. The company is now involved in building new infrastructure in Europe, Texas, and Ohio, further expanding its presence. Resources will also be invested in accelerating R&D in chitosan and adjacent technologies, adding to its intellectual property portfolio.
Commenting on the news, Craig Kasberg said: “We’ve already demonstrated it’s possible to make our biomolecular solutions outcompete. Now, we’re building infrastructure that’ll allow us to better serve customers who operate in critical industries providing the clean water, agriculture production, and materials necessary for everyday life.”
FinSMEs
06/02/2025